Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Securities code: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) securities abbreviation: Hunan Fangsheng Pharmaceutical Co.Ltd(603998) Announcement No.: 2022032
Hunan Fangsheng Pharmaceutical Co.Ltd(603998)
About the securities regulatory authorities and exchanges
Announcement of punishment or supervision measures and rectification
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Whereas Hunan Fangsheng Pharmaceutical Co.Ltd(603998) (hereinafter referred to as “the company” or ” Hunan Fangsheng Pharmaceutical Co.Ltd(603998) “) intends to apply to the China Securities Regulatory Commission (hereinafter referred to as “the CSRC”) for non-public offering of shares, the punishment or regulatory measures taken by the securities regulatory authorities and exchanges in the past five years and the implementation of corresponding rectification are hereby announced as follows:
1、 The company has been punished by the securities regulatory authorities and the exchange in the past five years
The company has not been punished by the securities regulatory department and Shanghai Stock Exchange in the past five years.
2、 Regulatory measures and rectification measures taken by securities regulatory authorities and exchanges in the past five years
(I) on June 17, 2019, Shanghai Stock Exchange took disciplinary action
1. Content of punishment
On June 17, 2019, Shanghai Stock Exchange (hereinafter referred to as “Shanghai Stock Exchange”)
Issued the decision on circulating a notice of criticism against Hunan Fangsheng Pharmaceutical Co.Ltd(603998) and relevant responsible persons ([2019] No. 41), which mainly includes:
The company was not prudent in handling the suspension of major asset restructuring, and the information disclosure and risk disclosure related to the restructuring were insufficient, which affected the investors’ right to know and trading rights. Zhang Qinghua, the then chairman of the company, as the main person in charge of the company and the first person responsible for information disclosure, and Xiao Hanqing, the then Secretary of the board of directors, as the specific person in charge of the company’s information disclosure, failed to
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
Be diligent and responsible for the above violations of the company.
In view of the above violation facts and circumstances, the Shanghai Stock Exchange made the following disciplinary decision: criticize Hunan Fangsheng Pharmaceutical Co.Ltd(603998) and its then chairman Zhang Qinghua and then Secretary of the board of directors Xiao Hanqing.
2. Rectification
In view of the above problems, the company attaches great importance to, practically improves and strengthens its own work, draws lessons from experience, strengthens prior communication with trading parties and professional institutions, and organizes relevant personnel to seriously study the stock listing rules of Shanghai Stock Exchange and the administrative measures for major asset restructuring of listed companies Relevant provisions such as the guidelines for the suspension and resumption of trading of Listed Companies in Shanghai Stock Exchange in planning major events and the guidelines for the governance of listed companies, so as to improve their professional quality and sense of responsibility. The company will take warning, standardize its operation and earnestly fulfill its obligation of information disclosure in strict accordance with laws, regulations and the provisions of the stock listing rules of Shanghai Stock Exchange; Directors, supervisors and senior managers shall strictly perform their obligations of loyalty and diligence, promote the standardized operation of the company, and ensure that the company discloses all major information in a timely, fair, true, accurate and complete manner.
(II) on May 28, 2021, Shanghai Stock Exchange gave an oral warning
1. Warning content
On May 28, 2021, the Shanghai Stock Exchange
He Shiyu, then Secretary of the board of directors, gave an oral warning, mainly including:
(1) The company treated the capital contribution of Caixin Securities Co., Ltd., a priority limited partner in the same Fangsheng (Zhuhai) pharmaceutical industry investment partnership (limited partnership), as a priority limited partner in terms of information disclosure, but in terms of financial treatment, its capital contribution was regarded as a creditor’s right, and the information disclosure of the company was inconsistent with the actual situation;
(2) All the partners joined Fangsheng (Zhuhai) pharmaceutical in December 2018
The loss bearing arrangement of industrial investment partnership (limited partnership) has signed a memorandum. Since the company calculates the investment with the equity method, the way of loss bearing may affect the company’s investment
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) HUNANFANGSHENG PHARMACEUTICAL CO., LTD.
The recognition of income, but the company did not disclose it in time through the temporary announcement, and the information disclosure of the company was not timely.
The company’s information disclosure on matters related to investment in M & a funds violates the relevant provisions of the business guidelines on information disclosure of cooperative investment matters between listed companies and private equity funds.
2. Rectification
After receiving the oral warning, the company attached great importance to it, organized the securities affairs staff and other relevant personnel to strengthen the in-depth study of the business related to information disclosure, and required to seriously implement the rectification measures, improve the level and normative awareness of the company’s information disclosure, ensure the effective implementation of the information disclosure system, and ensure the accuracy and timeliness of information disclosure.
In addition to the above circumstances, the company has not been subject to other regulatory measures taken by the securities regulatory authorities and exchanges in the past five years.
It is hereby announced
Hunan Fangsheng Pharmaceutical Co.Ltd(603998) board of directors
March 6, 2022
